Treatment of RMS by conversion therapy

The invention relates to treatment of recurrent multiple sclerosis (RMS) by conversion therapy. In particular, the present application relates to an anti-CD20 monoclonal antibody ofalimumab for use in the treatment or prevention of recurrent multiple sclerosis, wherein ofalimumab is for use in a pat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	MERSCHHEIMKE, MAX, ZURN MICHAEL, RAMANATHAN KARTHIK, HERRIN DAVID A, PINGILI RAFFAELE, BUG MICHAEL
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention relates to treatment of recurrent multiple sclerosis (RMS) by conversion therapy. In particular, the present application relates to an anti-CD20 monoclonal antibody ofalimumab for use in the treatment or prevention of recurrent multiple sclerosis, wherein ofalimumab is for use in a patient that has been treated with a disease correction therapy other than ofalimumab. 本申请涉及通过转换疗法治疗复发型多发性硬化症(RMS)。本申请具体涉及用于治疗或预防复发型多发性硬化症的抗-CD20单克隆抗体奥法木单抗，其中奥法木单抗用于已经用奥法木单抗以外的疾病修正疗法治疗过的患者。